MAOB and Parkinson disease: Safinamide inhibits MAO-B and modulates glutamate release in a highly selective and reversible manner, and it can be used as an adjuvant to L-dopa alone or in conjunction with other medications to improve 'on' time in people with PD who are in the middle to late stages of the disease [70,71].